Inactive Instrument

Aevi Genomic Medicine, Inc.

Equities

US00835P1057

Biotechnology & Medical Research

Aevi Genomic Medicine, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2019

May 14, 2019 at 08:01 am EDT

Aevi Genomic Medicine, Inc. announced earnings results for the first quarter ended March 31, 2019. For the first quarter, the company announced operating loss was USD 4.854 million compared to USD 8.735 million a year ago. Net loss was USD 4.839 million compared to USD 8.709 million a year ago. Basic loss per share was USD 0.07 compared to USD 0.15 a year ago.

Latest news about Aevi Genomic Medicine, Inc.

Aevi Genomic Medicine, LLC(NasdaqGM:GNMX) dropped from S&P TMI Index	20-02-04	CI
Aevi Genomic Medicine, Inc. Announces Resignation of Directors	20-02-03	CI
Aevi Genomic Medicine, LLC(NasdaqCM:GNMX) dropped from NASDAQ Composite Index	20-02-03	CI
Cerecor Inc. completed the acquisition of Aevi Genomic Medicine, Inc..	20-02-02	CI
Aevi Genomic Medicine, Inc. Doses the First Patient with AEVI-002 in A Phase Ib Clinical Trial	19-11-22	CI
Aevi Genomic Medicine, Inc. Reports Earnings Results for the Third Quarter Ended September 30, 2019	19-11-14	CI
Cerecor Inc. entered into a definitive merger agreement to acquire Aevi Genomic Medicine, Inc. for $15.6 million.	19-11-13	CI
Aevi Genomic Medicine, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2019	19-08-13	CI
Aevi Genomic Medicine, Inc. Obtains License for Medi2338, Phase 2-Ready Fully Human Monoclonal Antibody That Targets Interleukin 18 (IL-18)	19-08-07	CI
Declaration of Voting Results by Aevi Genomic Medicine, Inc.	19-06-24	CI
Aevi Genomic Medicine, Inc. Announces Executive Changes	19-05-21	CI
Aevi Genomic Medicine, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2019	19-05-14	CI
The Children’s Hospital Nominates Board Candidate to Aevi Genomic	19-03-29	CI
Aevi Genomic Medicine, Inc. Reports Earnings Results for the Full Year Ended December 31, 2018	19-03-29	CI
Aevi Genomic Medicine, Inc. Auditor Raises 'Going Concern' Doubt	19-03-28	CI
Aevi Genomic Medicine Announces Top-Line Results from Placebo-Controlled ASCEND Trial of AEVI-001 in Children with ADHD	19-01-02	CI
Transcript : Aevi Genomic Medicine, Inc. - Special Call	18-11-29
Aevi Genomic Medicine, Inc. Reports Consolidated Unaudited Earnings Results for the Third Quarter and Nine Months Ended September 30, 2018	18-11-01	CI
Aevi Genomic Medicine, Inc. Announces Completion of Enrollment for Part B of the Ascend Trial	18-10-15	CI
Aevi Genomic Medicine, Inc. announced that it has received $5 million in funding from The Children's Hospital Of Philadelphia Foundation, Endowment Arm	18-08-14	CI
Aevi Genomic Medicine, Inc. Announces Completion of Enrollment in Part A of Phase 2 ASCEND Trial in ADHD	18-08-14	CI
Aevi Genomic Medicine, Inc. Reports Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2018	18-08-02	CI
Aevi Genomic Medicine, Inc. Announces Novel Co-crystal Version of AEVI-001	18-07-19	CI
Aevi Genomic Medicine, Inc. Announces the Retirement of Wilbur H. Gantz's from the Board of Directors and Audit Committee	18-06-22	CI
Aevi Genomic Medicine Provides Update on Sample Size Re-Estimation for Phase 2 ASCEND Trial in ADHD	18-06-12	CI

Chart Aevi Genomic Medicine, Inc.

Duration

Period

More charts

Company Profile

Aevi Genomic Medicine, Inc., formerly Medgenics, Inc., is focused on genomic medicine. The Company is engaged in unlocking the potential of genomic medicine to translate genetic discoveries into therapies. The Company is engaged in developing therapies for children and adults with pediatric onset life altering diseases. The Company's product candidates include AEVI-001 and AEVI-002. The Company's research and development efforts leverage an internal genomics platform and a collaboration with the Center for Applied Genomics (CAG) at The Children's Hospital of Philadelphia (CHOP). .

Sector

Biotechnology & Medical Research

More about the company

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
IQVIA HOLDINGS INC.	+1.51%	42.75B
MODERNA, INC.	+8.57%	41.34B
LONZA GROUP AG	+49.22%	41.61B
CELLTRION, INC.	-12.36%	26.59B
ICON PUBLIC LIMITED COMPANY	+8.92%	25.49B
ALNYLAM PHARMACEUTICALS, INC.	-25.13%	18.12B
MEDPACE HOLDINGS, INC.	+29.17%	12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.12%	11.76B
UNITED THERAPEUTICS CORPORATION	+6.35%	11B

Other Biotechnology & Medical Research